4,643,430 Shares in Pharvaris N.V. $PHVS Purchased by venBio Partners LLC

venBio Partners LLC acquired a new stake in Pharvaris N.V. (NASDAQ:PHVS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,643,430 shares of the company’s stock, valued at approximately $160,569,809. Pharvaris comprises about 0.0% of venBio Partners LLC’s holdings, making the stock its biggest holding. venBio Partners LLC owned approximately 7.10% of Pharvaris as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PHVS. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the second quarter valued at approximately $196,000. Seven Fleet Capital Management LP raised its stake in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after purchasing an additional 457,804 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Pharvaris during the second quarter worth about $4,800,000. Elmind Capital LP acquired a new stake in Pharvaris in the second quarter valued at about $18,180,435. Finally, 5AM Venture Management LLC acquired a new stake in Pharvaris in the 2nd quarter worth about $27,581,008.

Pharvaris Price Performance

PHVS traded down $1.68 during trading on Friday, hitting $35.32. The stock had a trading volume of 478,862 shares, compared to its average volume of 337,589. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -11.58 and a beta of -2.31. Pharvaris N.V. has a one year low of $20.65 and a one year high of $38.13. The company has a 50 day moving average price of $34.56 and a 200-day moving average price of $30.71.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pharvaris news, insider Anna Nijdam sold 2,670 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anne Lesage sold 30,703 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the transaction, the insider directly owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 121,325 shares of company stock worth $4,270,425 in the last three months. 11.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

PHVS has been the topic of several recent research reports. New Street Research set a $60.00 price objective on shares of Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company began coverage on Pharvaris in a research report on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price target for the company. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. Citizens Jmp increased their price target on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.